Dozens of early-stage drug makers and other biotech firms are planning to list in Hong Kong over the next two years, say executives, bankers and investors, as the exchange pushes through its biggest regulatory overhaul in decades.
WSJ.com: World Markets, Wall Street Journal: World Markets
Thu, 03/22/2018 - 3:57am
Dozens of early-stage drug makers and other biotech firms are planning to list in Hong Kong over the next two years, say executives, bankers and investors, as the exchange pushes through its biggest regulatory overhaul in decades.